Evaluation of intravenous amoxicillin-clavulanate use in two Canadian hospitals
Maggie Wong, Sangita Malhotra, Kevin Afra
TL;DR
This paper evaluates the use of intravenous amoxicillin-clavulanate in Canadian hospitals as an alternative to other antibiotics.
Contribution
The study introduces and evaluates the clinical use of a newly available antibiotic in Canada.
Findings
Most patients were successfully switched from other antibiotics to amoxicillin-clavulanate.
The drug was effective for treating respiratory and skin infections.
It offers a good alternative due to increasing resistance to other antibiotics.
Abstract
We describe our experience with intravenous amoxicillin-clavulanate, which is new to the Canadian market. The majority of patients were successfully de-escalated from piperacillin-tazobactam or a carbapenem for respiratory infections or skin and soft tissue infections. Intravenous amoxicillin-clavulanate provides a good alternative in an era of rising Pseudomonas aeruginosa resistance.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsAntibiotic Resistance in Bacteria · Antibiotics Pharmacokinetics and Efficacy · Pneumonia and Respiratory Infections